logo logo
Search: Organ site Search: Tumor / Syndrome
or
WHO Classification of Tumours

Myeloproliferative neoplasms
    9875/3 Chronic myelogenous leukaemia, BCR-ABL1 positive
    9963/3 Chronic neutrophilic leukaemia
    9950/3 Polycythaemia vera
    9961/3 Primary myelofibrosis
    9962/3 Essential thrombocythaemia
    9964/3 Chronic eosinophilic leukaemia, NOS
    9975/3 Myeloproliferative neoplasm, unclassifiable

Mastocytosis
    9740/1 Cutaneous mastocytosis
    9741/3 Systemic mastocytosis
        9741/3 Indolent systemic mastocytosis
        9741/3 Systemic mastocytosis with associated clonal haematological non-mast-cell lineage disease
        9741/3 Aggressive systemic mastocytosis
        9742/3 Mast cell leukaemia
    9740/3 Mast cell sarcoma
    9740/1 Extracutaneous mastocytoma

Myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB and FGFR1
    9965/3 Myeloid and lymphoid neoplasms with PDGFRA rearrangement
    9966/3 Myeloid neoplasms with PDGFRB rearrangement
    9967/3 Myeloid and lymphoid neoplasms with FGFR1 abnormalities

Myelodysplastic/myeloproliferative neoplasms
    9945/3 Chronic myelomonocytic leukaemia
    9876/3 Atypical chronic myeloid leukaemia, BCR-ABL1 negative
    9946/3 Juvenile myelomonocytic leukaemia
    9975/3 Myelodysplastic/myeloproliferative neoplasm, unclassifiable
        9982/3 Refractory anaemia with ring sideroblasts associated with marked thrombocytosis

Myelodysplastic syndromes
    Refractory cytopenia with unilineage dysplasia
        9980/3 Refractory anaemia
        9991/3 Refractory neutropenia
        9992/3 Refractory thrombocytopenia
    9982/3 Refractory anaemia with ring sideroblasts
    9985/3 Refractory cytopenia with multilineage dysplasia
    9983/3 Refractory anaemia with excess blasts
    9986/3 Myelodysplastic syndrome associated with isolated del(5q)
    9989/3 Myelodysplastic syndrome, unclassifiable
        Childhood myelodysplastic syndrome
        9985/3 Refractory cytopenia of childhood

Acute myeloid leukaemia (AML) and related precursor neoplasms
AML with recurrent genetic abnormalities1 2
    9896/3 Acute myeloid leukaemia with t(8;21)(q22;q22); RUNX1-RUNX1T1
    9871/3 Acute myeloid leukaemia with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11
    9866/3 Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA
    9897/3 Acute myeloid leukaemia with t(9;11)(p22;q23); MLLT3-MLL
    9865/3 Acute myeloid leukaemia with t(6;9)(p23;q34); DEK-NUP214
    9869/3 Acute myeloid leukaemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1
    9911/3 Acute myeloid leukaemia (megakaryoblastic) with t(1;22)(p13;q13); RBM15-MKL1
    9861/3 AML with mutated NPM1
    9861/3 AML with mutated CEBPA

    9895/3 Acute myeloid leukaemia (AML) with myelodysplasia-related changes

    9920/3 Therapy-related myeloid neoplasms

    9861/3 Acute myeloid leukaemia, NOS
        9872/3 Acute myeloid leukaemia with minimal differentiation
        9873/3 Acute myeloid leukaemia without maturation
        9874/3 Acute myeloid leukaemia with maturation
        9867/3 Acute myelomonocytic leukaemia
        9891/3 Acute monoblastic and monocytic leukaemia
        9840/3 Acute erythroid leukaemia
        9910/3 Acute megakaryoblastic leukaemia
        9870/3 Acute basophilic leukaemia
        9931/3 Acute panmyelosis with myelofibrosis

    9930/3 Myeloid sarcoma

    9898/1 Transient abnormal myelopoiesis associated with Down syndrome
    9898/3 Myeloid leukaemia associated with Down syndrome

    9727/3 Blastic plasmacytoid dendritic cell neoplasm

Acute leukaemias of ambiguous lineage
    9801/3 Acute undifferentiated leukaemia
    9806/3 Mixed phenotype acute leukaemia with t(9;22)(q34;q11.2); BCR-ABL1
    9807/3 Mixed phenotype acute leukaemia with t(v;11q23); MLL rearranged
    9808/3 Mixed phenotype acute leukaemia, B/myeloid, NOS
    9809/3 Mixed phenotype acute leukaemia, T/myeloid, NOS
    0000/0 Natural killer (NK) cell lymphoblastic leukaemia/lymphoma

Precursor lymphoid neoplasms
    9811/3 B lymphoblastic leukaemia/lymphoma, NOS
    9812/3 B lymphoblastic leukaemia/lymphoma with t(9;22)(q34;q11.2); BCR-ABL1
    9813/3 B lymphoblastic leukaemia/lymphoma with t(v;11q23); MLL rearranged
    9814/3 B lymphoblastic leukaemia/lymphoma with t(12;21)(p13;q22); TEL-AML1 (ETV6-RUNX1)
    9815/3 B lymphoblastic leukaemia/lymphoma with hyperdiploidy
    9816/3 B lymphoblastic leukaemia/lymphoma with hypodiploidy (hypodiploid ALL)
    9817/3 B lymphoblastic leukaemia/lymphoma with t(5;14)(q31;q32) IL3-IGH
    9818/3 B lymphoblastic leukaemia/lymphoma with t(1;19)(q23;p13.3); E2A-PBX1 (TCF3-PBX1)

    9837/3 T Lymphoblastic leukaemia/lymphoma

Mature B-cell neoplasms
    0000/0 Monoclonal B-cell lymphocytosis (MBL)
    9823/3 Chronic lymphocytic leukaemia / small lymphocytic lymphoma
    9833/3 B-cell prolymphocytic leukaemia
    9689/3 Splenic marginal zone lymphoma
    9940/3 Hairy cell leukaemia
    9591/3 Splenic B-cell lymphoma/leukaemia, unclassifiable
        9591/3 Splenic diffuse red pulp small B-cell lymphoma
        9591/3 Hairy cell leukaemia-variant
    9671/3 Lymphoplasmacytic lymphoma
        9761/3 Waldenström macroglobulinemia
    9762/3 Heavy chain diseases
        9764/3 Alpha heavy chain disease
        9762/3 Gamma heavy chain disease
        9762/3 Mu heavy chain disease
    9765/1 Monoclonal gammopathy of undetermined significance
    9732/3 Plasma cell myeloma
        9732/3 Asymptomatic (smoldering) myeloma
        9732/3 Non-secretory myeloma
        9733/3 Plasma cell leukaemia
    9731/3 Solitary plasmacytoma of bone
    9734/3 Extraosseous plasmacytoma
    9769/1 Immunoglobulin deposition diseases
        9769/1 Primary amyloidosis
        9769/1 Monoclonal light and heavy chain deposition diseases
         Osteosclerotic myeloma
    9699/3 Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma)
    9699/3 Nodal marginal zone lymphoma
        9699/3 Paediatric nodal marginal zone lymphoma
    9690/3 Follicular lymphoma
        9690/3 Paediatric follicular lymphoma
        9690/3 Primary intestinal follicular lymphoma
        0000/0 Intrafollicular neoplasia/"in situ" follicular lymphoma
    9597/3 Primary cutaneous follicle centre lymphoma
    9673/3 Mantle cell lymphoma
        0000/0 "In situ" mantle cell lymphoma
    9680/3 Diffuse large B-cell lymphoma (DLBCL), NOS
        9688/3 T-cell/histiocyte rich large B-cell lymphoma
        9680/3 Primary DLBCL of the central nervous system (CNS)
        9680/3 Primary cutaneous DLBCL, leg type
        9680/3 Epstein-Barr virus (EBV) positive diffuse large B-cell lymphoma of the elderly
        9680/3 DLBCL associated with chronic inflammation
    9766/1 Lymphomatoid granulomatosis
    9679/3 Primary mediastinal (thymic) large B-cell lymphoma
    9712/3 Intravascular large B-cell lymphoma
    9737/3 ALK positive large B-cell lymphoma
    9735/3 Plasmablastic lymphoma
    9738/3 Large B-cell lymphoma arising in HHV8-associated multicentric Castleman disease
    9678/3 Primary effusion lymphoma
    9687/3 Burkitt lymphoma
    9680/3 B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma
    9596/3 B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma

Mature T-cell and NK-cell neoplasms
    9834/3 T-cell prolymphocytic leukaemia
    9831/3 T-cell large granular lymphocytic leukaemia
    9831/3 Chronic lymphoproliferative disorder of NK-cells
    9948/3 Aggressive NK-cell leukaemia
    9724/3 Systemic EBV+ T-cell lymphoproliferative disease of childhood
    9725/3 Hydroa vacciniforme-like lymphoma
    9827/3 Adult T-cell leukaemia/lymphoma
    9719/3 Extranodal NK/T cell lymphoma, nasal type
    9717/3 Enteropathy-associated T-cell lymphoma
    9716/3 Hepatosplenic T-cell lymphoma
    9708/3 Subcutaneous panniculitis-like T-cell lymphoma
    9700/3 Mycosis fungoides
    9701/3 Sézary syndrome
    Primary cutaneous CD30 positive T-cell lymphoproliferative disorders
        9718/1 Lymphomatoid papulosis
        9718/3 Primary cutaneous anaplastic large cell lymphoma
    9726/3 Primary cutaneous gamma-delta T-cell lymphoma
    9709/3 Primary cutaneous CD8 positive aggressive epidermotropic cytotoxic T-cell lymphoma
    9709/3 Primary cutaneous CD4 positive small/medium T-cell lymphoma
    9702/3 Peripheral T-cell lymphoma, (NOS)
    9705/3 Angioimmunoblastic T-cell lymphoma
    9714/3 Anaplastic large cell lymphoma, ALK positive
    9702/3 Anaplastic large cell lymphoma, ALK negative

Hodgkin lymphoma
    9659/3 Nodular lymphocyte predominant Hodgkin lymphoma
    9650/3 Classical Hodgkin lymphoma
        9663/3 Nodular sclerosis classical Hodgkin lymphoma
        9651/3 Lymphocyte-rich classical Hodgkin lymphoma
        9652/3 Mixed cellularity classical Hodgkin lymphoma
        9653/3 Lymphocyte-depleted classical Hodgkin lymphoma

Histiocytic and dendritic cell neoplasms
    9755/3 Histiocytic sarcoma
    9751/3 Langerhans cell histiocytosis
    9756/3 Langerhans cell sarcoma
    9757/3 Interdigitating dendritic cell sarcoma
    9758/3 Follicular dendritic cell sarcoma
    9759/3 Fibroblastic reticular cell tumour
    9757/3 Indeterminate dendritic cell tumour
    0000/0 Disseminated juvenile xanthogranuloma

Post-transplant lymphoproliferative disorders (PTLD)
    Early lesions
        9971/1 Plasmacytic hyperplasia
        9971/1 Infectious mononucleosis-like PTLD
    9971/3 Polymorphic PTLD
     Monomorphic PTLD (B- and T/NK-cell types) *
    9650/3 Classical Hodgkin lymphoma type PTLD *

Other immunodeficiency-associated lymphoproliferative disorders
     Other iatrogenic immunodeficiency-associated lymphoproliferative disorders
     Lymphoproliferative diseases associated with primary immune disorders
     Lymphomas associated with HIV infection

*These lesions are classified according to the leukaemia or lymphoma to which they correspond and are assigned the respective ICD-O codes

The italicized histologic subtypes are provisional entities for which the WHO Working Group felt there was insufficient evidence to recognize as distinct diseases at this time.